Aronex Pharmaceuticals Appoints John H. Waterman as Vice President, Regulatory Affairs
- Nycomed Amersham Professional Brings Over 20 Years of Experience in Regulatory Affairs -
THE WOODLANDS, Texas, April 27 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq: ARNX - news) today announced the appointment of John H. Waterman as the Company's Vice President, Regulatory Affairs. This appointment further strengthens the Company's management team and provides the Company with substantial regulatory affairs expertise for the approaching commercialization of its two lead clinical products.
''We are delighted to have Jack Waterman join our management team,'' said Geoffrey F. Cox, Ph.D., Chairman and CEO of Aronex Pharmaceuticals. ''Jack has an impressive record of developing, implementing and directing regulatory systems to ensure compliance with the requirements of the Food and Drug Administration and its international counterparts. His extensive experience working with the FDA while at Nycomed Amersham will be invaluable to Aronex Pharmaceuticals as we advance NYOTRAN(TM) and ATRAGEN(R) toward commercialization.''
Mr. Waterman has more than twenty years of U.S. and international regulatory affairs experience. He served most recently as Vice President, Regulatory Affairs and Quality Assurance at Nycomed Amersham plc (formerly Amersham Holdings). At Amersham, he was responsible for drug regulatory affairs, environment regulatory affairs, quality assurance, and pharmacy practice regulatory affairs, and coordinated the filings of five NDAs. He was also instrumental in the design of a fast-track NDA review/approval strategy that resulted in a six-month approval for Ceretec(R) and recognition by the FDA for Amersham's innovative and cooperative efforts.
Mr. Waterman's earlier positions include Manager, Regulatory Affairs at American Critical Care Division of American Hospital Supply Corp. and Manager, Drug Regulatory Affairs at Astra Pharmaceutical Products, Inc. He holds an MS degree in Operations and Technology Management from Illinois Institute of Technology and a BA in Biology from Hope College.
Aronex Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes proprietary innovative medicines to treat cancer and infectious diseases. Aronex Pharmaceuticals currently has four products in clinical development, two of which are in an advanced stage, as well as a pipeline of additional products.
Any statements which are not historical facts contained in this release are forward looking statements that involve risks and uncertainties, including but not limited to those relating to product demand, pricing, market acceptance, the effect of economic conditions, intellectual property rights and litigation, clinical trials, governmental regulation, competitive products, risks in product and technology development, the results of financing efforts, the ability to complete transactions and other risks identified in the Company's Securities and Exchange Commission filings.
SOURCE: Aronex Pharmaceuticals, Inc.
-------------------------------------------------------------------------------- |
